Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Induction and Consolidation Regimens in AML (AML 10)
NCT00002549Phase 3Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 1993
- Modality
- DNA Intercalators/Alkylators
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of idarubicin, mitoxantrone and daunorubicin in acute myeloid leukemia (AML) (6 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Complete Remission Rate. Status: unknown.
02
Drugs
idarubicinmitoxantronedaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00002549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002549.